Microtubule-targeting agents and their impact on cancer treatment
Language English Country Germany Media print-electronic
Document type Journal Article, Review
PubMed
32414588
DOI
10.1016/j.ejcb.2020.151075
PII: S0171-9335(20)30014-5
Knihovny.cz E-resources
- Keywords
- Cancer metastasis, Cancer therapy, Microtubule-targeting agents, Migrastatics,
- MeSH
- Antineoplastic Agents pharmacology MeSH
- Humans MeSH
- Microtubules drug effects MeSH
- Neoplasms drug therapy MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Antineoplastic Agents MeSH
Microtubule-targeting agents (MTAs) constitute a diverse group of chemical compounds that bind to microtubules and affect their properties and function. Disruption of microtubules induces various cellular responses often leading to cell cycle arrest or cell death, the most common effect of MTAs. MTAs have found a plethora of practical applications in weed control, as fungicides and antiparasitics, and particularly in cancer treatment. Here we summarize the current knowledge of MTAs, the mechanisms of action and their role in cancer treatment. We further outline the potential use of MTAs in anti-metastatic therapy based on inhibition of cancer cell migration and invasiveness. The two main problems associated with cancer therapy by MTAs are high systemic toxicity and development of resistance. Toxic side effects of MTAs can be, at least partly, eliminated by conjugation of the drugs with various carriers. Moreover, some of the novel MTAs overcome the resistance mediated by both multidrug resistance transporters as well as overexpression of specific β-tubulin types. In anti-metastatic therapy, MTAs should be combined with other drugs to target all modes of cancer cell invasion.
References provided by Crossref.org
Click estradiol dimers with novel aromatic bridging units: synthesis and anticancer evaluation
